Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received two drug license suspension orders from the Drugs Control Administration in Telangana. The first order suspends the license for three days at a store in Garimilla Mancherial Exp, Karimnagar, received on May 21, 2025. The second order suspends the license for one day at a store on Main Road Bodhan, Nizamabad. Both actions were taken under Rule 65 of the Drugs and Cosmetics Act, 1940. The total potential revenue loss is estimated at around Rs 0.66 lakhs (Rs 0.42 lakhs + Rs 0.24 lakhs), which is negligible given the size of Medplus's operations across India.
The financial impact on the company is extremely small, with combined potential revenue loss of only about Rs 0.66 lakhs from these two short suspensions. Shareholders are unlikely to see any meaningful effect on the stock or business, as this is a routine regulatory matter limited to two stores and a few days.